^
Association details:
| Biomarker: | MYC expression + BCL2 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Retrospective Analysis of Clinical Outcomes of Utilizing R-CHOP Plus Zanubrutinib for High-Risk Diffuse Large B Cell Lymphoma Patients with Extranodal Involvement or MYC/BCL2 Double Expression
Published date:
11/02/2023
Excerpt:
The combination of 4 cycles of R-CHOP regimen with zanubrutinib in the induction treatment of DLBCL patients with high-risk factors, such as extranodal involvement or MYC/BCL2 double expression, has shown promising clinical outcomes especially in older or unfit/frail patients.
Secondary therapy:
R-CHOP
DOI:
https://doi.org/10.1182/blood-2023-182704
